RT Journal Article
SR Electronic
T1 AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005829
DO 10.1136/jitc-2022-005829
VO 11
IS 10
A1 Frentzas, Sophia
A1 Kao, Steven
A1 Gao, Rang
A1 Zheng, Hao
A1 Rizwan, Ahsan
A1 Budha, Nageshwar
A1 de la Hoz Pedroza, Luz
A1 Tan, Wei
A1 Meniawy, Tarek
YR 2023
UL http://jitc.bmj.com/content/11/10/e005829.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.